160 related articles for article (PubMed ID: 1665293)
21. 1,3,4-Oxadiazole, 1,3,4-thiadiazole, and 1,2,4-triazole analogs of the fenamates: in vitro inhibition of cyclooxygenase and 5-lipoxygenase activities.
Boschelli DH; Connor DT; Bornemeier DA; Dyer RD; Kennedy JA; Kuipers PJ; Okonkwo GC; Schrier DJ; Wright CD
J Med Chem; 1993 Jun; 36(13):1802-10. PubMed ID: 8515419
[TBL] [Abstract][Full Text] [Related]
22. WY-50,295 tromethamine, a novel, orally active 5-lipoxygenase inhibitor: biochemical characterization and antiallergic activity.
Grimes D; Sturm RJ; Marinari LR; Carlson RP; Berkenkopf JW; Musser JH; Kreft AF; Weichman BM
Eur J Pharmacol; 1993 May; 236(2):217-28. PubMed ID: 8391458
[TBL] [Abstract][Full Text] [Related]
23. Design, synthesis, and biological evaluation of some novel indolizine derivatives as dual cyclooxygenase and lipoxygenase inhibitor for anti-inflammatory activity.
Shrivastava SK; Srivastava P; Bandresh R; Tripathi PN; Tripathi A
Bioorg Med Chem; 2017 Aug; 25(16):4424-4432. PubMed ID: 28669741
[TBL] [Abstract][Full Text] [Related]
24. Dibenzoxepinone hydroxylamines and hydroxamic acids: dual inhibitors of cyclooxygenase and 5-lipoxygenase with potent topical antiinflammatory activity.
Hamer RR; Tegeler JJ; Kurtz ES; Allen RC; Bailey SC; Elliott ME; Hellyer L; Helsley GC; Przekop P; Freed BS; White J; Martin LL
J Med Chem; 1996 Jan; 39(1):246-52. PubMed ID: 8568814
[TBL] [Abstract][Full Text] [Related]
25. Effect of a 5-lipoxygenase (5-LO)/cyclooxygenase (CO) inhibitor, WY-47, 288, on cutaneous models of inflammation.
Carlson RP; O'Neill-Davis L; Calhoun W; Datko L; Musser JH; Kreft AF; Chang JY
Agents Actions; 1989 Mar; 26(3-4):319-28. PubMed ID: 2500009
[TBL] [Abstract][Full Text] [Related]
26. Determination of the eicosanoid response to inflammatory stimuli in whole blood and its pharmacological modulation ex vivo.
von Aulock S; Hermann C; Hartung T
J Immunol Methods; 2003 Jun; 277(1-2):53-63. PubMed ID: 12799039
[TBL] [Abstract][Full Text] [Related]
27. Pharmacological profile of SK&F 105809, a dual inhibitor of arachidonic acid metabolism.
Hanna N; Marshall PJ; Newton J; Schwartz L; Kirsh R; Dimartino MJ; Adams J; Bender P; Griswold DE
Drugs Exp Clin Res; 1990; 16(4):137-47. PubMed ID: 2127565
[TBL] [Abstract][Full Text] [Related]
28. Selective inhibition of arachidonate 5-lipoxygenase by novel acetohydroxamic acids: biochemical assessment in vitro and ex vivo.
Tateson JE; Randall RW; Reynolds CH; Jackson WP; Bhattacherjee P; Salmon JA; Garland LG
Br J Pharmacol; 1988 Jun; 94(2):528-39. PubMed ID: 2840160
[TBL] [Abstract][Full Text] [Related]
29. In vitro effects of E3040, a dual inhibitor of 5-lipoxygenase and thromboxane A(2) synthetase, on eicosanoid production.
Oketani K; Nagakura N; Harada K; Inoue T
Eur J Pharmacol; 2001 Jun; 422(1-3):209-16. PubMed ID: 11430933
[TBL] [Abstract][Full Text] [Related]
30. Pharmacology of the pyrroloimidazole, SK&F 105809--I. Inhibition of inflammatory cytokine production and of 5-lipoxygenase- and cyclooxygenase-mediated metabolism of arachidonic acid.
Marshall PJ; Griswold DE; Breton J; Webb EF; Hillegass LM; Sarau HM; Newton J; Lee JC; Bender PE; Hanna N
Biochem Pharmacol; 1991 Jul; 42(4):813-24. PubMed ID: 1907824
[TBL] [Abstract][Full Text] [Related]
31. Phorbol ester-induced dermal inflammation in mice: evaluation of inhibitors of 5-lipoxygenase and antagonists of leukotriene B4 receptor.
Rao TS; Yu SS; Djuric SW; Isakson PC
J Lipid Mediat Cell Signal; 1994 Sep; 10(3):213-28. PubMed ID: 7812673
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of 5-lipoxygenase activity by the natural anti-inflammatory compound aethiopinone.
Benrezzouk R; Terencio MC; Ferrandiz ML; Hernandez-Perez M; Rabanal R; Alcaraz MJ
Inflamm Res; 2001 Feb; 50(2):96-101. PubMed ID: 11289660
[TBL] [Abstract][Full Text] [Related]
33. Molecular modelling insights into a physiologically favourable approach to eicosanoid biosynthesis inhibition through novel thieno[2,3-b]pyridine derivatives.
Mohamed MS; Mansour YE; Amin HK; El-Araby ME
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):755-767. PubMed ID: 29651867
[TBL] [Abstract][Full Text] [Related]
34. Structure-activity relationships of (E)-3-(1,4-benzoquinonyl)-2-[(3-pyridyl)-alkyl]-2-propenoic acid derivatives that inhibit both 5-lipoxygenase and thromboxane A2 synthetase.
Hibi S; Okamoto Y; Tagami K; Numata H; Kobayashi N; Shinoda M; Kawahara T; Harada K; Miyamoto K; Yamatsu I
J Med Chem; 1996 Aug; 39(16):3148-57. PubMed ID: 8759636
[TBL] [Abstract][Full Text] [Related]
35. Differential inhibition of thromboxane B2 and leukotriene B4 biosynthesis by two naturally occurring acetylenic fatty acids.
Croft KD; Beilin LJ; Ford GL
Biochim Biophys Acta; 1987 Oct; 921(3):621-4. PubMed ID: 2822134
[TBL] [Abstract][Full Text] [Related]
36. Comparison of several new 5-lipoxygenase inhibitors in a rat Arthus pleurisy model.
Berkenkopf JW; Weichman BM
Eur J Pharmacol; 1991 Jan; 193(1):29-34. PubMed ID: 1646730
[TBL] [Abstract][Full Text] [Related]
37. Effect of dihomogammalinolenic acid and its 15-lipoxygenase metabolite on eicosanoid metabolism by human mononuclear leukocytes in vitro: selective inhibition of the 5-lipoxygenase pathway.
Iversen L; Fogh K; Kragballe K
Arch Dermatol Res; 1992; 284(4):222-6. PubMed ID: 1329675
[TBL] [Abstract][Full Text] [Related]
38. CGS 22745: a selective orally active inhibitor of 5-lipoxygenase.
Kimble E; Kowalski T; White D; Raychauduri A; Pastor G; Chertock H; Lee W; Neale R; Hamdan A; Wasley J
Agents Actions; 1991 Sep; 34(1-2):125-8. PubMed ID: 1665286
[TBL] [Abstract][Full Text] [Related]
39. Effects of the cyclooxygenase-2 inhibitor NS-398 on thromboxane and leukotriene synthesis in rat peritoneal cells.
Schuligoi R; Amann R; Prenn C; Peskar BA
Inflamm Res; 1998 May; 47(5):227-30. PubMed ID: 9657255
[TBL] [Abstract][Full Text] [Related]
40. 5-lipoxygenase inhibitory activity of zileuton.
Carter GW; Young PR; Albert DH; Bouska J; Dyer R; Bell RL; Summers JB; Brooks DW
J Pharmacol Exp Ther; 1991 Mar; 256(3):929-37. PubMed ID: 1848634
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
